Bristol-Myers to buy Celgene in a $74 billion deal

Bristol-Myers Squibb is buying cancer drugmaker Celgene in a cash and stock deal valued at $74 billion, the companies announced Thursday.

Source link

Leave a Comment

China warns pig trade against African swine fever cover-ups as Taiwan concerns growTips on how to limit excessive screen time